Becton, Dickinson and Company (BDX)
Largest Insider Buys in Sector
BDX Stock Price History Chart
BDX Stock Performance
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer …
Insider Activity of Becton, Dickinson and Company
Over the last 12 months, insiders at Becton, Dickinson and Company have bought $0 and sold $4.42M worth of Becton, Dickinson and Company stock.
On average, over the past 5 years, insiders at Becton, Dickinson and Company have bought $0 and sold $11.83M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 30 shares for transaction amount of $7,439 was made by BURZIK CATHERINE M (director) on 2019‑04‑16.
List of Insider Buy and Sell Transactions, Becton, Dickinson and Company
| 2024-12-19 | Sale | EVP & President, Medical | 2,838 0.001% | $223.33 | $633,811 | +2.20% | ||
| 2024-12-09 | Sale | EVP and President, EMEA | 638 0.0002% | $219.03 | $139,741 | +1.18% | ||
| 2024-12-06 | Sale | EVP and President, EMEA | 4,483 0.0016% | $221.01 | $990,788 | +2.54% | ||
| 2024-12-06 | Sale | EVP and Chief People Officer | 1,000 0.0003% | $220.49 | $220,490 | +2.54% | ||
| 2024-12-05 | Sale | EVP and Chief ISC Officer | 1,500 0.0005% | $220.25 | $330,375 | +1.49% | ||
| 2024-06-10 | Sale | SVP,Controller&Chief Acct Off | 300 0.0001% | $239.31 | $71,793 | -2.09% | ||
| 2024-05-15 | Sale | EVP and President EMEA | 3,300 0.0011% | $236.73 | $781,224 | -1.13% | ||
| 2024-05-13 | Sale | EVP and President EMEA | 3,300 0.0011% | $236.70 | $781,121 | -0.94% | ||
| 2024-04-30 | Sale | EVP & President Medical | 1,715 0.0006% | $232.81 | $399,269 | +0.08% | ||
| 2024-03-14 | Sale | SVP,Controller&Chief Acct Off | 282 <0.0001% | $238.29 | $67,198 | -0.99% | ||
| 2023-12-11 | Sale | EVP & President Medical | 1,239 0.0004% | $232.46 | $288,018 | +1.60% | ||
| 2023-11-28 | Sale | EVP & President Interventional | 2,156 0.0007% | $238.47 | $514,141 | -0.29% | ||
| 2023-09-05 | Sale | EVP & President Interventional | 459 0.0002% | $274.48 | $125,986 | -12.73% | ||
| 2023-08-28 | Sale | director | 848 0.0003% | $281.66 | $238,848 | -15.36% | ||
| 2023-08-11 | Sale | EVP & President, Life Sciences | 2,974 0.001% | $277.85 | $826,326 | -15.40% | ||
| 2023-08-08 | Sale | EVP & President Medical | 1,300 0.0005% | $277.13 | $360,269 | -15.02% | ||
| 2023-02-03 | Sale | EVP & President Interventional | 1,421 0.0005% | $248.60 | $353,261 | +3.07% | ||
| 2022-08-15 | Sale | Chairman, CEO and President | 9,500 0.0033% | $265.13 | $2.52M | -5.02% | ||
| 2022-08-15 | Sale | EVP & President, Life Sciences | 475 0.0002% | $265.00 | $125,875 | -5.02% | ||
| 2022-08-09 | Sale | Executive Vice President | 1,652 0.0006% | $260.00 | $429,520 | -0.74% |
Insider Historical Profitability
| OVERLOCK WILARD J JR | director | 21091 0.0073% | $226.42 | 2 | 2 | +1.24% |
| BURZIK CATHERINE M | director | 10007 0.0035% | $226.42 | 3 | 1 | +5.53% |
| UGGLAS MARGERETHA AF | director | 10000 0.0034% | $226.42 | 1 | 0 | +22.54% |
| Minehan Cathy E. | director | 3000 0.001% | $226.42 | 2 | 0 | +2.05% |
| Melcher David F | director | 2728 0.0009% | $226.42 | 1 | 0 | +8.76% |
Institutional Investor Ownership
| The Vanguard Group | $6.48B | 9.06 | 26.18M | +0.23% | +$15.17M | 0.12 | |
| BlackRock | $5.64B | 7.89 | 22.81M | +0.15% | +$8.37M | 0.12 | |
| State Street | $3.35B | 4.68 | 13.53M | +4.77% | +$152.38M | 0.14 | |
| Morgan Stanley | $2.65B | 3.71 | 10.71M | +0.01% | +$339,254.02 | 0.2 | |
| T. Rowe Price | $2.5B | 3.5 | 10.12M | -2.56% | -$65.71M | 0.31 |